KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Current Taxes (2017 - 2025)

Historic Current Taxes for Sarepta Therapeutics (SRPT) over the last 7 years, with Q3 2025 value amounting to $9.1 million.

  • Sarepta Therapeutics' Current Taxes changed N/A to $9.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.1 million, marking a year-over-year change of. This contributed to the annual value of $17.4 million for FY2024, which is 2633.3% up from last year.
  • According to the latest figures from Q3 2025, Sarepta Therapeutics' Current Taxes is $9.1 million.
  • In the past 5 years, Sarepta Therapeutics' Current Taxes ranged from a high of $79.9 million in Q1 2025 and a low of $216000.0 during Q4 2021
  • For the 5-year period, Sarepta Therapeutics' Current Taxes averaged around $19.6 million, with its median value being $16.7 million (2023).
  • Its Current Taxes has fluctuated over the past 5 years, first surged by 569675.93% in 2022, then skyrocketed by 994.33% in 2023.
  • Over the past 5 years, Sarepta Therapeutics' Current Taxes (Quarter) stood at $216000.0 in 2021, then surged by 5696.76% to $12.5 million in 2022, then grew by 9.94% to $13.8 million in 2023, then rose by 26.33% to $17.4 million in 2024, then plummeted by 47.73% to $9.1 million in 2025.
  • Its last three reported values are $9.1 million in Q3 2025, $18.7 million for Q2 2025, and $79.9 million during Q1 2025.